Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

61 results about "TEBIPENEM PIVOXIL" patented technology

Tebipenem (brand name Orapenem) is a broad-spectrum orally-administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics. ... Tebipenem is formulated as the ester tebipenem pivoxil due to the better absorption and improved bioavailability of this form.

Tebipenem pivoxil industrial preparation method

The invention relates to the field of medical chemistry, and specifically relates to a tebipenem pivoxil industrial preparation method. The method comprises the following steps: tebipenem, a solvent I, salt, and a phase-transfer catalyst are mixed, and a salt-forming reaction is carried out under normal temperature; chloromethylpivalate is added under a same temperature, and an esterification reaction is carried out; when the reaction is finished, extraction and concentration are carried out; a solvent II is dropped for crystallization; and filtering is carried out, such that tebipenem pivoxil is obtained. With the method, operation is simple, and complicated operations of pH regulation and repeated extraction are avoided. Post-treatment solvent dose is low, such that resource is saved, and environment pollution is reduced. Chloromethylpivalate property is stable, and normal-temperature reaction requirement is low. Product yield is high, and a maximal yield can be higher than 88%. The purity of synthesized tebipenem pivoxil can be higher than 99.7%. Without refining, the obtained tebipenem pivoxil can be used for preparing medicine preparations as a raw material medicine satisfying medical requirements, and the medicine preparation can be safely used by patients. The method is suitable for industrial productions.
Owner:LUNAN PHARMA GROUP CORPORATION

Preparation method of antibacterial agent

The invention discloses a preparation method of an antibacterial medicament tebipenem pivoxil. (4R,5R,6S)-3-((diphenyl-phosphoroso-carbonyl)oxyl)-6-((R)-1-ethoxyl)-4-methyl-7-carbonyl-1-azabicyclo[3.2.0]heptane-2-alkenyl-2-carboxylic acid p-nitro ester(6-MAP(I)) serving as a raw material reacts with 1-(4,5-dihydro-2-thiazolinyl)-3-sulfydryl azetidine hydrochloride (II) in the presence of alkali to obtain (4R,5S,6S)-3-((1-(4,5-dihydro-2-thiazolinyl)-3-azetidine) sulfenyl)-6-((R)-1-ethoxy)-4-methyl-7-oxygen-1-azabicyclo[3.2.0]heptane-2-alkenyl-2-carboxylic acid p-nitro ester (III); the protecting group of the compound (III) is removed under the catalytic hydrogenation condition to obtain (4R,5S,6S)-3-((1-(4,50dihydro-2-thiazolinyl)-3-azetidine)sulfenyl)-6-((R)-1-ethoxy)-4-methyl-7-oxygen-1-azabicyclo[3.2.0]heptane-2-alkenyl-2-carboxylic acid (IV); and the compound (IV) reacts with chloromethyl pivalate and sodium iodide or potassium iodide in the presence of alkali to obtain tebipenem pivoxil (V). According to the preparation method, the selected initial raw materials are low in price and easily available, so that the synthesizing route is simplified, the raw material utilization and total yield can be improved; and the intermediate substance obtained in the reaction is purified by using a re-crystallization method with high yield, less three wastes are generated in the reacting process, and the low cost is advantageous to industrial production.
Owner:GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products